Volume 26, Number 3—March 2020
Research
Pregnancy Outcomes among Women Receiving rVSVΔ-ZEBOV-GP Ebola Vaccine during the Sierra Leone Trial to Introduce a Vaccine against Ebola
Table 2
Characteristic | Live birth | Pregnancy loss | Total | Barnard’s exact p value |
---|---|---|---|---|
Immediate vaccinated, no. | 17 | 14 | 31 | 1 |
High viremia risk | 5 (56) | 4 (44) | 9 | NA |
Low viremia risk |
12 (55) |
10 (45) |
22 |
NA |
Deferred crossover vaccinated, no. | 12 | 5 | 17 | 0.75 |
High viremia risk | 6 (75) | 2 (25) | 8 | NA |
Low viremia risk |
6 (67) |
3 (33) |
9 |
NA |
Total vaccinated, no. | 29 | 19 | 48 | 0.69 |
High viremia risk | 11 (65) | 6 (35) | 17 | NA |
Low viremia risk | 18 (58) | 13 (42) | 31 | NA |
*Values are no. (%) except as indicated. NA, not applicable.
†High viremia risk is defined as estimated date of conception before vaccination or 0–14 days after vaccination. Low viremia risk is defined as estimated date of conception 15–60 days after vaccination.
1These first authors contributed equally to this article.
2These authors were co–principal investigators.
Page created: February 20, 2020
Page updated: February 20, 2020
Page reviewed: February 20, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.